155 results
P
pacientes con COVID-19
I/C
inhibidores de la enzima convertidora de angiotensina, bloqueadores del receptor de angiotensina II, placebo o ningún tratamiento
O
efectos sobre la COVID-19
P
patients with de novo IAs
I/C
systematic review and meta-analysis of existing de novo IA cohorts, initial IAs in the middle cerebral artery
O
de novo IAs
P
mujeres postmenopáusicas
I/C
uso de estrógenos
O
infección del tracto urinario sintomática
P
patients with COVID-19
I/C
diabetes, no diabetes
O
mortality
P
pacientes sometidos a cirugía
I/C
intervenciones con ejercicio, controlados
O
reducción de la sarcopenia
P
people with non-exudative age-related macular degeneration (AMD)
I/C
photobiomodulation (PBM) therapy, standard care, sham treatment, or no treatment
O
best-corrected visual acuity (BCVA); contrast sensitivity; near vision; low luminance density score; reading speed; vision-related quality of life score; and adverse events such as progression of AMD and conversion to exudative AMD
P
patients with knee osteoarthritis
I/C
offloader knee braces, use of offloader knee braces vs. no use
O
physical function, pain, quality of life, adverse events
P
patients with carious lesions
I/C
stepwise removal technique, complete removal technique
O
pulp exposure, signs and symptoms of pulp disease, restoration failure
P
patients undergoing orthognathic surgery
I/C
long-term antibiotic prophylaxis, short-term antibiotic prophylaxis
O
surgical site infection, hospital stay longer than two days
P
adult patients with generalized anxiety disorder
I/C
vortioxetine, standard psychopharmacological treatment
O
response to treatment, anxious symptoms, nausea